178 related articles for article (PubMed ID: 3856277)
1. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside.
Hellström I; Brankovan V; Hellström KE
Proc Natl Acad Sci U S A; 1985 Mar; 82(5):1499-502. PubMed ID: 3856277
[TBL] [Abstract][Full Text] [Related]
2. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis.
Cheresh DA; Honsik CJ; Staffileno LK; Jung G; Reisfeld RA
Proc Natl Acad Sci U S A; 1985 Aug; 82(15):5155-9. PubMed ID: 3860849
[TBL] [Abstract][Full Text] [Related]
3. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.
Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ
Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201
[TBL] [Abstract][Full Text] [Related]
4. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.
Chapman PB; Lonberg M; Houghton AN
Cancer Res; 1990 Mar; 50(5):1503-9. PubMed ID: 2105840
[TBL] [Abstract][Full Text] [Related]
5. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of chimeric anti-(ganglioside GD3) antibody KM871: antitumor activity in xenograft model of melanoma and effector function analysis.
Kanazawa J; Ohta S; Shitara K; Fujita F; Fujita M; Hanai N; Akinaga S; Okabe M
Cancer Immunol Immunother; 2000 Jul; 49(4-5):253-8. PubMed ID: 10941908
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.
Hellström I; Beaumier PL; Hellström KE
Proc Natl Acad Sci U S A; 1986 Sep; 83(18):7059-63. PubMed ID: 3462743
[TBL] [Abstract][Full Text] [Related]
9. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.
Ramos AS; Parise CB; Travassos LR; Han SW; de Campos-Lima PO; de Moraes JZ
Cancer Sci; 2011 Jan; 102(1):64-70. PubMed ID: 21070480
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte-dependent antibodies to antigen 3.1, a cell-surface antigen expressed by a subgroup of human melanomas.
Hellström I; Hellström KE; Yeh MY
Int J Cancer; 1981 Mar; 27(3):281-5. PubMed ID: 6169659
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.
Ohta S; Honda A; Tokutake Y; Yoshida H; Hanai N
Cancer Immunol Immunother; 1993; 36(4):260-6. PubMed ID: 8439988
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity.
Thurin J; Thurin M; Kimoto Y; Herlyn M; Lubeck MD; Elder DE; Smereczynska M; Karlsson KA; Clark WM; Steplewski Z
Cancer Res; 1987 Mar; 47(5):1229-33. PubMed ID: 3815333
[TBL] [Abstract][Full Text] [Related]
13. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Woodhouse CS; Morgan AC
Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
[TBL] [Abstract][Full Text] [Related]
14. Human monoclonal antibody to tumor-associated ganglioside GD2.
Katano M; Saxton RE; Irie RF
J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419
[TBL] [Abstract][Full Text] [Related]
15. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a.
Mayer P; Handgretinger R; Bruchelt G; Schaber B; Rassner G; Fierlbeck G
Melanoma Res; 1994 Apr; 4(2):101-6. PubMed ID: 8069095
[TBL] [Abstract][Full Text] [Related]
16. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.
Ruf P; Schäfer B; Eissler N; Mocikat R; Hess J; Plöscher M; Wosch S; Suckstorff I; Zehetmeier C; Lindhofer H
J Transl Med; 2012 Nov; 10():219. PubMed ID: 23134699
[TBL] [Abstract][Full Text] [Related]
17. Human monoclonal antibody to tumor-associated ganglioside GD2: suppressed growth of human melanoma in nude mice.
Katano M; Irie RF
Immunol Lett; 1984; 8(4):169-74. PubMed ID: 6542067
[TBL] [Abstract][Full Text] [Related]
18. Analysis of a murine anti-ganglioside GD2 monoclonal antibody expressing both IgG2a and IgG3 isotypes: monoclonality, apoptosis triggering, and activation of cellular cytotoxicity on human melanoma cells.
Lin CC; Shen YC; Chuang CK; Liao SK
Adv Exp Med Biol; 2001; 491():419-29. PubMed ID: 14533812
[TBL] [Abstract][Full Text] [Related]
19. Treatment of human metastatic melanoma with mouse monoclonal antibodies against GD3 ganglioside.
Houghton AN; Bajorin DF; Lonberg M; Chapman P
Prog Clin Biol Res; 1989; 288():383-90. PubMed ID: 2654956
[No Abstract] [Full Text] [Related]
20. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors.
Bergman I; Basse PH; Barmada MA; Griffin JA; Cheung NK
Cancer Immunol Immunother; 2000 Jul; 49(4-5):259-66. PubMed ID: 10941909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
